imatinib mesylate has been researched along with Acro-Osteolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, E; Bernal, S; Bredrup, C; Gladkauskas, T; Iznardo, H; Mascaró, JM; Roé, E | 1 |
| Bredrup, C; Bruland, O; Cristea, I; Houge, G; Høvding, G; Lee, S; McGaughran, J; Rødahl, E; Sapkota, D; Steen, VM; Stokowy, T; Tveit, KS; Xu, L | 1 |
2 other study(ies) available for imatinib mesylate and Acro-Osteolysis
| Article | Year |
|---|---|
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
Topics: Acro-Osteolysis; Dasatinib; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Progeria; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Skin Abnormalities; Young Adult | 2022 |
A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
Topics: Acro-Osteolysis; Adult; Aging; Apoptosis; Cockayne Syndrome; Female; Genetic Predisposition to Disease; HeLa Cells; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myofibromatosis; Phenotype; Phosphorylation; Progeria; Protein Interaction Maps; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction | 2019 |